Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666256 | 1.00 | EPHX2 (0.54) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL12891255 | 1.00 | EPHX2 (0.54) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706976 | 1.00 | EPHX2 (0.54) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706974 | 1.00 | EPHX2 (0.54) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL16944361 | 1.00 | EPHX2 (0.54) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706958 | 0.98 | EPHX2 (0.52) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706990 | 0.98 | EPHX2 (0.52) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706991 | 0.98 | EPHX2 (0.52) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706988 | 0.98 | EPHX2 (0.52) | EPHX2ADRA1APRMT1CYP1A2FAAH | |
| SCHEMBL13706967 | 0.97 | PRMT1 (0.51) | EPHX2ADRA1APRMT1CYP1A2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-2910570-B1 | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS (DK) | 2016-10-12 | — | — | EP | disclosed |
| EP-2910569-B1 | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2910571-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | disclosed |
| EP-2910569-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910571-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910570-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| US-7893017-B2 | Acylation; point mutations; site-directed mutagenesis; hyperglycemia; diabetes | NOVO NORDISK A/S (DK) | 2011-02-22 | — | — | US | disclosed |
| US-20080182785-A1 | Protracted Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182785-A1 | Protracted Glp-1 Compounds | GLP1R, GIPR, GRPR | EPHX2 4719/4885ADRA1A 808/4885PRMT1 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.